Skip to navigation Skip to content

News

Share

MS Trial Alert: Investigators Recruiting for Phase 3 Trial Comparing Experimental Fenebrutinib to Ocrevus® in Primary Progressive MS

April 14, 2021

SUMMARY: Investigators in the U.S. and abroad are recruiting 946 people with primary progressive MS for a study comparing investigational oral fenebrutinib with Ocrevus® (ocrelizumab - Genentech, a member of the Roche Group). The study – also called FENtrepid – is sponsored by F. Hoffmann-La Roche.
 
DETAILS
Rationale: Fenebrutinib inhibits an enzyme called “Bruton’s tyrosine kinase,” reducing the activation of B cells, which are immune cells that play a role in the response that affects the brain and spinal cord in MS. Fenebrutinib also inhibits immune cells in the brain called microglia, which have been linked to MS progression. Fenebrutinib is one of several “BTK” inhibitors being tested in clinical trials involving people with different types of MS.
 
Eligibility and Details: Participants should be 18 to 65 years old, and diagnosed with primary progressive MS.
 
All participants will receive active treatment. They will be randomly assigned to receive either oral fenebrutinib along with a placebo matching intravenous (infused into the vein) Ocrevus, or intravenous Ocrevus along with a placebo matching oral fenebrutinib. Treatment will last 120 weeks.
 
The primary outcome of the study will compare how these treatments affect disability progression using a composite measure that combines the EDSS scale of disability progression with measures of walking and hand function. Secondary outcomes include safety, changes in brain tissue volume, and cognition. The study involves up to 20 visits to the study site, and will involve MRI scans, blood draws, clinical exams, and questionnaires.
 
Please note: This study requires in-person visits to the study site. Precautions are being taken to reduce the on-site risks of exposure to COVID-19.
 
Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please visit the study listing on clinicaltrials.gov, call 888-662-6728 or email global-roche-genentech-trials@gene.com.

In the U.S., sites are enrolling in the following cities:
Fullerton, California
Maitland, Florida
Orlando, Florida
Tampa, Florida
Vero Beach, Florida
Indianapolis, Indiana
Kansas City, Kansas
Golden Valley, Minnesota
Saint Louis, Missouri
Las Vegas, Nevada
Amherst, New York
Charlotte, North Carolina
Raleigh, North Carolina
Cincinnati, Ohio
Cordova, Tennessee
Knoxville, Tennessee
Houston, Texas
Sherman, Texas
Kirkland, Washington
Seattle, Washington
Charleston, West Virginia
Milwaukee, Wisconsin
 
Download a brochure that discusses issues to think about when considering enrolling in an MS clinical trial (PDF).
 
Without participants in research studies, MS research would come to a standstill. Read more here.
 
 

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 800-344-4867.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.